336 related articles for article (PubMed ID: 35859169)
1. Mechanisms of APOBEC3 mutagenesis in human cancer cells.
Petljak M; Dananberg A; Chu K; Bergstrom EN; Striepen J; von Morgen P; Chen Y; Shah H; Sale JE; Alexandrov LB; Stratton MR; Maciejowski J
Nature; 2022 Jul; 607(7920):799-807. PubMed ID: 35859169
[TBL] [Abstract][Full Text] [Related]
2. Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.
Vural S; Simon R; Krushkal J
Hum Genomics; 2018 Apr; 12(1):20. PubMed ID: 29642934
[TBL] [Abstract][Full Text] [Related]
3. Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer.
Petljak M; Green AM; Maciejowski J; Weitzman MD
Nat Genet; 2022 Nov; 54(11):1599-1608. PubMed ID: 36280735
[TBL] [Abstract][Full Text] [Related]
4. Competition for DNA binding between the genome protector replication protein A and the genome modifying APOBEC3 single-stranded DNA deaminases.
Wong L; Sami A; Chelico L
Nucleic Acids Res; 2022 Nov; 50(21):12039-12057. PubMed ID: 36444883
[TBL] [Abstract][Full Text] [Related]
5. Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers.
DeWeerd RA; Németh E; Póti Á; Petryk N; Chen CL; Hyrien O; Szüts D; Green AM
Cell Rep; 2022 Mar; 38(12):110555. PubMed ID: 35320711
[TBL] [Abstract][Full Text] [Related]
6. Monitoring APOBEC3A protein levels in human cancer cells.
Dananberg A; Maciejowski J
Methods Cell Biol; 2024; 182():313-327. PubMed ID: 38359985
[TBL] [Abstract][Full Text] [Related]
7. Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA.
Bergstrom EN; Luebeck J; Petljak M; Khandekar A; Barnes M; Zhang T; Steele CD; Pillay N; Landi MT; Bafna V; Mischel PS; Harris RS; Alexandrov LB
Nature; 2022 Feb; 602(7897):510-517. PubMed ID: 35140399
[TBL] [Abstract][Full Text] [Related]
8. The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead.
Granadillo Rodríguez M; Flath B; Chelico L
Open Biol; 2020 Dec; 10(12):200188. PubMed ID: 33292100
[TBL] [Abstract][Full Text] [Related]
9. Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis.
Petljak M; Alexandrov LB; Brammeld JS; Price S; Wedge DC; Grossmann S; Dawson KJ; Ju YS; Iorio F; Tubio JMC; Koh CC; Georgakopoulos-Soares I; Rodríguez-Martín B; Otlu B; O'Meara S; Butler AP; Menzies A; Bhosle SG; Raine K; Jones DR; Teague JW; Beal K; Latimer C; O'Neill L; Zamora J; Anderson E; Patel N; Maddison M; Ng BL; Graham J; Garnett MJ; McDermott U; Nik-Zainal S; Campbell PJ; Stratton MR
Cell; 2019 Mar; 176(6):1282-1294.e20. PubMed ID: 30849372
[TBL] [Abstract][Full Text] [Related]
10. Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer.
Carpenter MA; Temiz NA; Ibrahim MA; Jarvis MC; Brown MR; Argyris PP; Brown WL; Starrett GJ; Yee D; Harris RS
PLoS Genet; 2023 Nov; 19(11):e1011043. PubMed ID: 38033156
[TBL] [Abstract][Full Text] [Related]
11. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo.
Law EK; Levin-Klein R; Jarvis MC; Kim H; Argyris PP; Carpenter MA; Starrett GJ; Temiz NA; Larson LK; Durfee C; Burns MB; Vogel RI; Stavrou S; Aguilera AN; Wagner S; Largaespada DA; Starr TK; Ross SR; Harris RS
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32870257
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential.
Butler K; Banday AR
J Hematol Oncol; 2023 Mar; 16(1):31. PubMed ID: 36978147
[TBL] [Abstract][Full Text] [Related]
13. Involvement of APOBEC3A/B Deletion in Mouse Mammary Tumor Virus (MMTV)-like Positive Human Breast Cancer.
de Sousa Pereira N; Vitiello GAF; Amarante MK
Diagnostics (Basel); 2023 Mar; 13(6):. PubMed ID: 36980505
[TBL] [Abstract][Full Text] [Related]
14. Roles of APOBEC3A and APOBEC3B in Human Papillomavirus Infection and Disease Progression.
Warren CJ; Westrich JA; Doorslaer KV; Pyeon D
Viruses; 2017 Aug; 9(8):. PubMed ID: 28825669
[TBL] [Abstract][Full Text] [Related]
15. APOBEC3 mutational signatures are associated with extensive and diverse genomic instability across multiple tumour types.
Jakobsdottir GM; Brewer DS; Cooper C; Green C; Wedge DC
BMC Biol; 2022 May; 20(1):117. PubMed ID: 35597990
[TBL] [Abstract][Full Text] [Related]
16. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3A damages the cellular genome during DNA replication.
Green AM; Landry S; Budagyan K; Avgousti DC; Shalhout S; Bhagwat AS; Weitzman MD
Cell Cycle; 2016; 15(7):998-1008. PubMed ID: 26918916
[TBL] [Abstract][Full Text] [Related]
18. APOBEC Enzymes as Targets for Virus and Cancer Therapy.
Olson ME; Harris RS; Harki DA
Cell Chem Biol; 2018 Jan; 25(1):36-49. PubMed ID: 29153851
[TBL] [Abstract][Full Text] [Related]
19. Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes.
Sanchez A; Ortega P; Sakhtemani R; Manjunath L; Oh S; Bournique E; Becker A; Kim K; Durfee C; Temiz NA; Chen XS; Harris RS; Lawrence MS; Buisson R
Nat Commun; 2024 Mar; 15(1):2370. PubMed ID: 38499542
[TBL] [Abstract][Full Text] [Related]
20. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
